Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.49 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.39 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.36 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 3/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16822326 | 0.86 | KMT2A (0.49) | KMT2AGFERFGFR1TBXA2RSMN1; SMN2 | |
| SCHEMBL19911434 | 0.85 | KMT2A (0.51) | KMT2AGFERSMN1; SMN2MEN1GRIN2B | |
| SCHEMBL19848123 | 0.82 | KMT2A (0.46) | KMT2AGFERMEN1GRIN2BKCNH2 | |
| SCHEMBL12502297 | 0.79 | FABP4 (0.40) | KMT2AGFERFGFR1SMN1; SMN2ASAH1 | |
| SCHEMBL31450450 | 0.79 | GGPS1 (0.45) | KMT2AGFERFGFR1SMN1; SMN2IDO1 | |
| SCHEMBL1304008 | 0.77 | GFER (0.45) | KMT2AGFERSMN1; SMN2GRIN2BIDO1 | |
| SCHEMBL25224486 | 0.77 | FGFR1 (0.42) | KMT2AGFERFGFR1SMN1; SMN2ASAH1 | |
| SCHEMBL857765 | 0.74 | SMN1; SMN2 (0.61) | KMT2ASMN1; SMN2ASAH1MEN1 | |
| SCHEMBL29795599 | 0.73 | ASAH1 (0.62) | KMT2AGFERSMN1; SMN2ASAH1GRIN2B | |
| SCHEMBL28794626 | 0.73 | ASAH1 (0.62) | KMT2AGFERSMN1; SMN2ASAH1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219460-B1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | SITARI PHARMA INC (US) | 2025-02-26 | — | — | EP | claimed |
| EP-4219460-B1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | SITARI PHARMA INC (US) | 2025-02-26 | — | — | EP | disclosed |
| US-20250011324-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | SITARI PHARMA, INC., | 2025-01-09 | — | — | US | disclosed |
| US-12152026-B2 | Transglutaminase 2 (TG2) inhibitors | SITARI PHARMA, INC. (US) | 2024-11-26 | — | — | US | disclosed |
| EP-4219460-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | Sitari Pharma, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| US-11548892-B1 | Transglutaminase 2 (TG2) inhibitors | SITARI PHARMA, INC. (US) | 2023-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11548892-B1 | Transglutaminase 2 (TG2) inhibitors | TGM2, TGM3, TGM1 | KMT2A 787/4885GFER 1719/4885FGFR1 3924/4885 |
| US-12152026-B2 | Transglutaminase 2 (TG2) inhibitors | TGM2, TGM3, TGM1 | KMT2A 787/4885GFER 1719/4885FGFR1 3924/4885 |
| US-20250011324-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | TGM2, TGM3, TGM1 | KMT2A 787/4885GFER 1719/4885FGFR1 3924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.